DOCSLIB.ORG

Propantheline Bromide(BAN, Rinn)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Propantheline Bromide(BAN, Rinn) 1764 Gastrointestinal Drugs Potassium Acid Tartrate For the general properties of potassium salts, see p.1684, and of Propantheline Bromide (BAN, rINN) sodium salts, see p.1686. E336; Hydrogenvinan draselný; Kalii hydrogenotartras; Kalio- Bromuro de propantelina; Propanteliinibromidi; Propantelin Bro- vandenilio tartratas; Kalium Hydrotartaricum; Kálium-hidrogén- Preparations mür; Propantelinbromid; Propantelin-bromid; Propantelino bro- tartarát; Kaliumvätetartrat; Kaliumvetytartraatti; Potassium BPC 1973: Compound Effervescent Powder. midas; Propanthéline, bromure de; Propanthelini bromidum; Bitartrate (USAN); Potassium Hydrogen Tartrate; Potassium, hy- Proprietary Preparations (details are given in Part 3) Propanthelinii Bromidum; Propanthelinium-bromid. Di-isopro- drogénotartrate de; Potasu wodorowinian; Purified Cream of Gr.: Tr igolax. pylmethyl[2-(xanthen-9-ylcarbonyloxy)ethyl]ammonium bro- Ta r t ar ; Ta r t a r u s D ep u r at u s ; Ta r t r a t o á c i d o d e p o t a s io ; We i n - Multi-ingredient: Austria: Laxalpin; Fr.: Romarene; Philipp.: Castoria; mide. stein. UK: Jaaps Health Salt. Пропантелина Бромид Кислый Виннокислый Калий C23H30BrNO3 = 448.4. CAS — 298-50-0 (propantheline); 50-34-0 (propantheline C4H5KO6 = 188.2. Prifinium Bromide (rINN) bromide). CAS — 868-14-4. ATC — A03AB05. ATC — A12BA03. Bromuro de prifinio; PDB; Prifinii Bromidum; Prifinium, Bromure de; Pyrodifenium Bromide. 3-Diphenylmethylene-1,1-diethyl-2- ATC Vet — QA03AB05. ATC Vet — QA12BA03. methylpyrrolidinium bromide. Прифиния Бромид CH3 O OH C22H28BrN = 386.4. CAS — 10236-81-4 (prifinium); 4630-95-9 (prifinium O O + - + O K bromide). CH3 N − HO ATC — A03AB18. Br H3C CH OH O ATC Vet — QA03AB18. 3 H3C Pharmacopoeias. In Eur. (see p.vii) and US. O Ph. Eur. 6.2 (Potassium Hydrogen Tartrate). A white or almost CH white, crystalline powder or colourless crystals. Slightly soluble 3 in water; practically insoluble in alcohol. It dissolves in dilute Pharmacopoeias. In Chin., Eur. (see p.vii), Jpn, and US. Ph. Eur. 6.2 (Propantheline Bromide). A white or yellowish- solutions of mineral acids and alkali hydroxides. N+ CH3 USP 31 (Potassium Bitartrate). Colourless or slightly opaque white, slightly hygroscopic powder. Very soluble in water, in al- crystals or a white, crystalline powder. Slightly soluble in water; cohol, and in dichloromethane. Store in airtight containers. Br USP 31 (Propantheline Bromide). White or practically white, soluble in boiling water; very slightly soluble in alcohol. A satu- CH3 rated solution is acid to litmus. Store in airtight containers. odourless, crystals. Very soluble in water, in alcohol, and in chlo- roform; practically insoluble in ether and in benzene. Profile Potassium acid tartrate is given with sodium bicarbonate as a Adverse Effects, Treatment, and Precau- suppository for the treatment of constipation (p.1693) and for tions bowel evacuation before investigational procedures or surgery. Carbon dioxide gas is produced in the rectum, which stimulates As for Atropine Sulfate, p.1219. Contact dermatitis has defaecation within 5 to 30 minutes. Profile been reported after topical application of propantheline Potassium acid tartrate is used as a food additive and pharmaceu- Prifinium bromide is a quaternary ammonium antimuscarinic bromide. tical aid. with peripheral effects similar to those of atropine (p.1219). It is Buccal and oesophageal ulceration. Severe buccal mucosal structurally related to diphemanil metilsulfate (p.2295). 1 Potassium acid tartrate has been used as an ingredient of prepa- ulceration has been reported in a 95-year-old woman as a result rations for potassium supplementation, although other potassium Prifinium bromide is used to relieve smooth muscle spasms. Oral of retaining emepronium bromide tablets in her mouth, and re- salts are usually preferred. For the general properties of potassi- doses usually range from 90 to 180 mg daily in 3 divided doses. curred on giving propantheline bromide tablets. um salts, see p.1684. It has also been given rectally in a dose of 60 mg three or four 1. Huston GJ, et al. Anticholinergic drugs, buccal ulceration and times daily, or by subcutaneous, intramuscular, or intravenous in- mucosal potential difference. Postgrad Med J 1978; 54: 331–2. Preparations jection in a dose of 15 mg given 2 to 4 times daily. Preparations Interactions BPC 1968: Effervescent Potassium Tablets. As for antimuscarinics in general (see Atropine Sul- Proprietary Preparations (details are given in Part 3) Proprietary Preparations (details are given in Part 3) Fr.: Riabal†; Ital.: Riabal; Jpn: Padrin†; Mex.: Anespas; Rus.: Riabal fate, p.1220). Multi-ingredient: Austria: Lecicarbon; Braz.: Circanetten†; Varicell†; (Риабал); Thai.: Riabal†. Ital.: Potassion; Swed.: Relaxit; Thai.: Circanetten; USA: Ceo-Two. Pharmacokinetics Propantheline bromide is incompletely absorbed from Proglumide (BAN, USAN, rINN) the gastrointestinal tract and bioavailability is reported Potassium Sodium Tartrate CR-242; Proglumida; Proglumidum; W-5219; Xylamide. (±)-4- to be reduced by food; it is extensively metabolised in E337; Kalii natrii tartras; Kalio-natrio tartratas; Kalium Natrium Benzamido-N,N-dipropylglutaramic acid. the small intestine before absorption. The plasma elim- Tartaricum; Kálium-nátrium-tartarát; Kaliumnatriumtartraatti; Ka- Проглумид ination half-life after a single oral dose has been report- liumnatriumtartrat; Potassium et de sodium, tartrate de; Ro- ed to be about 2 to 3 hours. Propantheline is eliminated C18H26N2O4 = 334.4. chelle Salt; Seignette Salt; Sodii et Potassii Tartras; Sodium Potas- CAS — 6620-60-6. mainly in the urine as metabolites and less than 10% as sium Tartrate; Sodu potasu winian; Tartarus Natronatus; Tartrato ATC — A02BX06. unchanged drug. The duration of action is about 6 de potasio y de sodio; Vinan draselno-sodný. ATC Vet — QA02BX06. hours. Виннокислый Калий-натрий C H KNaO ,4H O = 282.2. Uses and Administration 4 4 6 2 H C CAS — 304-59-6 (anhydrous sodium potassium tartrate); 3 Propantheline bromide is a quaternary ammonium anti- 6381-59-5 (sodium potassium tartrate tetrahydrate); H3C muscarinic with peripheral effects similar to those of 6100-16-9 (sodium potassium tartrate tetrahydrate). N atropine (p.1219). It has been used as an antispasmodic (p.1692) for conditions associated with gastrointestinal O spasm, and as an adjunct in the treatment of peptic ul- O OH HN cer disease (p.1702). The usual initial oral dose is O- Na+ 15 mg three times daily, 30 to 60 minutes before meals, K+ -O O O and 30 mg at bedtime; doses of up to 120 mg daily may OH O HO be needed in some patients. In elderly patients, doses of 7.5 mg three times daily may be sufficient. Doses of (anhydrous sodium potassium tartrate) Pharmacopoeias. In Chin. and Jpn. 300 micrograms/kg (to a maximum of 15 mg) given 3 or 4 times daily have been used for the relief of gas- Pharmacopoeias. In Eur. (see p.vii) and US. Profile Proglumide is a cholecystokinin antagonist with an inhibitory ef- trointestinal spasm in children aged 1 month to 12 Ph. Eur. 6.2 (Potassium Sodium Tartrate Tetrahydrate). A white years; older children may be given the adult dose. or almost white, crystalline powder or colourless transparent fect on gastric secretion. It has been used in the treatment of pep- tic ulcer disease (p.1702) and other gastrointestinal disorders in crystals. Very soluble in water; practically insoluble in alcohol. Propantheline bromide has been used in the treatment usual doses of 400 mg two to four times daily by mouth before USP 31 (Potassium Sodium Tartrate). Colourless crystals or a of adult enuresis or urinary incontinence, and in hyper- meals; up to 800 mg three times daily may be given. It has also white, crystalline powder, with a cooling, saline taste. It efflo- been given by intramuscular or intravenous injection in a dose of hidrosis (see below), in doses similar to those given resces slightly in warm dry air, the crystals often being coated 400 to 800 mg daily. above. with a white powder. Soluble 1 in 1 of water; practically insolu- ble in alcohol. Store in airtight containers. Preparations Hyperhidrosis. Some antimuscarinics, including propanthe- line, have been applied topically in the treatment of hyperhidro- Profile Proprietary Preparations (details are given in Part 3) sis (p.1580). Adverse effects of antimuscarinics given by mouth Potassium sodium tartrate has been used as an osmotic laxative Austria: Milid; Ital.: Milid†; Port.: Milid†. generally preclude their use by this route, although oral propan- (p.1693). It is also used as a food additive. theline was used successfully to control excessive sweating in 2 Potassium Acid Tartrate/Ramosetron Hydrochloride 1765 patients with spinal cord injuries,1 and it is sometimes used in teric-coated tablet formulation, because of first-pass palliative care to control night sweats. The BNF notes that pro- metabolism, and does not appear to vary after single or pantheline may be used for gustatory sweating in patients with diabetic neuropathy. repeated doses. Rabeprazole is about 97% bound to O plasma proteins. It is extensively metabolised in the 1. Canaday BR, Stanford RH. Propantheline bromide in the man- O agement of hyperhidrosis associated with spinal cord injury. Ann liver by cytochrome P450 isoenzymes CYP2C19 and N Pharmacother 1995; 29: 489–92. CYP3A4 to the thioether, thioether carboxylic acid, H Urinary incontinence. In the UK, guidelines issued by NICE O sulfone, and desmethylthioether. Metabolites are ex- S suggest that propantheline should not be recommended for the creted principally in the urine (about 90%) with the re- treatment of urinary incontinence (p.2180) or overactive bladder 1 mainder in the faeces. The plasma half-life is about 1 in women; other antimuscarinics are preferred. O CH3 1. National Institute for Health and Clinical Excellence. Urinary in- hour, increased two to threefold in hepatic impairment, continence: the management of urinary incontinence in women 1.6 times in CYP2C19 slow metabolisers (see also Me- (issued October 2006). Available at: http://www.nice.org.uk/ Pharmacopoeias. In Eur. (see p.vii). nicemedia/pdf/CG40fullguideline.pdf (accessed 03/07/08) tabolism under Omeprazole, p.1755), and by 30% in Ph.
Load more

Recommended publications
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmacological Treatment of Urinary Incontinence
    Committee 8 Pharmacological Treatment of Urinary Incontinence Chairman KARL-ERIK ANDERSSON (USA) Co-Chairman C. R CHAPPLE (U.K) Members L. CARDOZO (U.K), F. C RUZ (Portugal), H. HASHIM (U.K), M.C. MICHEL (The Netherlands), C. TANNENBAUM (Canada), A.J. WEIN (USA) 631 CONTENTS A. INTRODUCTION X. OTHER DRUGS I. PUBLICATION SEARCHES XI. COMBINATIONS II. CENTRAL NERVOUS CONTROL XII. FUTURE POSSIBILITIES III.PERIPHERALNERVOUS CONTROL C.DRUGS USED FOR IV. PATHOGENESIS OF BLADDER TREATMENT OF STRESS CONTROL DISORDERS URINARY INCONTINENCE V. BLADDER CONTRACTION I. α-ADRENCEPTOR AGONISTS VI. MUSCARINIC RECEPTORS II. β-ADRENOCEPTOR ANTAGONISTS B. DRUGS USED FOR TREATMENT OF OVERACTIVE III. β-ADRENOCEPTOR AGONISTS BLADDER SYMPTOMS/ DETRUSOR OVERACTIVITY IV. SEROTONIN-NORADRENALINE UPTAKE INHIBITORS I. ANTIMUSCARINIC (ANTICHOLINERGIC) DRUGS D.DRUGS USED FOR II. DRUGS ACTING ON MEMBRANE TREATMENT OF CHANNELS OVERFLOW INCONTINENCE III. DRUGS WITH “MIXED” ACTION E. HORMONALTREATMENT OF URINARY INCONTINENCE IV. α-ADRENOCEPTOR (AR) ANTAGONISTS I. ESTROGENS V. β-ADRENOCEPTOR AGONISTS II. OTHER STEROID HORMONE VI. PHOSPHODIESTERASE (PDE) RECEPTOR LIGANDS INHIBITORS III. DESMOPRESSIN VII. ANTIDEPRESSANTS VIII. CYCLOOXYGENASE (COX) INHIBITORS F. CONSIDERATIONS IN THE ELDERLY IX. TOXINS REFERENCES 632 Pharmacological Treatment of Urinary Incontinence KARL-ERIK ANDERSSON C. R CHAPPLE, L. CARDOZO, F. CRUZ, H. HASHIM, M.C. MICHEL, C. TANNENBAUM, A.J. WEIN Table 1. ICI assessments 2008: Oxford guidelines (modified) A. INTRODUCTION Levels of evidence Level 1: Systematic reviews, meta-analyses, good The function of the lower urinary tract (LUT) is to store quality randomized controlled clinical trials and periodically release urine, and is dependent on (RCTs) the activity of smooth and striated muscles in the Level 2: RCTs , good quality prospective cohort bladder, urethra, and pelvic floor.
    [Show full text]
  • Management of Parkinson's Disease: an Evidence-Based Review
    Movement Disorders Vol. 17, Suppl. 4, 2002, p. i 2002 Movement Disorder Society Published by Wiley-Liss, Inc. DOI 10.1002/mds.5554 Editorial Management of Parkinson’s Disease: An Evidence-Based Review* Although Parkinson’s disease is still incurable, a large number tomatic control of Parkinson’s disease; prevention of motor com- of different treatments have become available to improve quality plications; control of motor complications; and control of non- of life and physical and psychological morbidity. Numerous jour- motor features. Based on a systematic review of the data, efficacy nal supplements have appeared in recent years highlighting one conclusions are provided. On the basis of a narrative non-system- or more of these and disparate treatment algorithms have prolifer- atic approach, statements on safety of the interventions are given ated. Although these are often quite useful, this “mentor analy- and finally, a qualitative approach is used to summarize the impli- sis” approach lacks the scientific rigor required by modern evi- cations for clinical practice and future research. dence-based medicine standards. The Movement Disorder Soci- This mammoth task has taken two years to complete and the ety, with generous but unrestricted support from representatives task force members, principal authors and contributors are to be of industry, have, therefore, commissioned a systematic review congratulated for their outstanding work. Physicians, the of the literature dealing with the efficacy and safety of available Parkinson’s disease research community and most of all patients treatments. The accompanying treatise is the result of a scrupu- themselves should welcome and embrace the salient findings of lous evaluation of the literature aimed at identifying those treat- this report as an effort to improve clinical practice.
    [Show full text]
  • Effect of Antispasmodic Agents for the Treatment of Irritable Bowel Syndrome
    PHARMACOTHERAPEUTICS pISSN 1975-8456 / eISSN 2093-5951 J Korean Med Assoc 2018 July; 61(7):428-434 https://doi.org/10.5124/jkma.2018.61.7.428 과민성 장증후군 치료에서 진경제의 효과 이 상 헌ㆍ지 삼 룡 | 인제대학교 의과대학 부산백병원 내과 Effect of antispasmodic agents for the treatment of irritable bowel syndrome Sang Heon Lee, MD · Sam Ryong Jee, MD Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS. Key Words: Parasympatholytics; Abdominal pain; Irritable bowel syndrome 서론 2005년 Cochrane 문헌고찰에서 일부 진경제는 복통과 전 반적인 증상 호전에 효과가 있다고 하였는데 약한 증거수 과민성 장증후군은 이전에는 ‘경련성 대장’이라고 불리 준이었다[4]. 2006년 유럽에서 시행한 체계적 문헌고찰에 었다. 그 뜻은 경련이 증상을 일으킨다는 뜻이다[1]. 지난 수 서는 9개의 위약군대조시험들이 표준화된 진단기준이 결여 십 년 동안 과민성 장증후군 환자에게 진경제를 사용하고 있 되어 있다는 제한점을 발견하였다[5].
    [Show full text]
  • Bulking Agents, Antispasmodics and Antidepressants for the Treatment of Irritable Bowel Syndrome (Review)
    Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (Review) Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JWM This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 3 http://www.thecochranelibrary.com Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 4 Figure1. ..................................... 7 DISCUSSION ..................................... 11 AUTHORS’CONCLUSIONS . 13 ACKNOWLEDGEMENTS . 13 REFERENCES ..................................... 14 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 83 Analysis 1.1. Comparison 1 Bulking agents: Abdominal pain, Outcome 1 Comparing nr(%) of successfully treated IBS patients..................................... 89 Analysis 1.2. Comparison 1 Bulking agents: Abdominal pain, Outcome 2 Comparing scores on abdominal pain in IBS patients..................................... 90 Analysis 2.1. Comparison 2 Bulking agents: Global assessment, Outcome 1 Comparing nr(%) of successfully
    [Show full text]